Ophthalmic surgery, lasers & imaging retina最新文献

{"title":"Universal Newborn Eye Screening in São Paulo, Brazil.","authors":"Pauline Scherm, Devi K Schwartz, Marcelo Alexandre Agra Cavalcante Costa, Homero Augusto de Miranda, Marco H Ji, Andrew A Moshfeghi, Jochen Kumm, Eric Nudleman, Emmett T Cunningham, Darius M Moshfeghi","doi":"10.3928/23258160-20260302-01","DOIUrl":"https://doi.org/10.3928/23258160-20260302-01","url":null,"abstract":"<p><p>This brief report describes the incidence and characteristics of ocular abnormalities in healthy term newborn infants (HTNI) in 5,000 consecutive eye examinations from a database of 32,000 infants from 17 hospitals in São Paulo, Brazil. Imaging consisted of five views of the retina (optic nerve center, superior, inferior, nasal, temporal) with 130° wide-angle lens and one view of the anterior segment in each eye. These images were curated on four separate occasions for the presence or absence of ocular abnormality by a pediatric retina specialist. All images were obtained within 72 hours of birth. A total of 59,792 images were curated: Right Eye Normal (21,473 images), Left Eye Normal (21,983 images), Right Eye Abnormal (8,397 images), Left Eye Abnormal (7,939 images). An ocular abnormality appeared in 37.7% of patients; 4.88% showed a referral-warranted pathology. Based on these data, it is not unreasonable to consider instituting universal newborn eye screening in HTNI.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-4"},"PeriodicalIF":1.1,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors Associated With the Development of Neovascular Glaucoma Following a Diagnosis of Proliferative Diabetic Retinopathy or Retinal Vein Occlusion.","authors":"Param Bhatter, Priya S Eppel, Sonia B Kim, Rishi P Singh, David C Kaelber, Katherine E Talcott","doi":"10.3928/23258160-20260311-01","DOIUrl":"https://doi.org/10.3928/23258160-20260311-01","url":null,"abstract":"<p><strong>Background and objective: </strong>This study aimed to evaluate cumulative incidence and risk factors for neovascular glaucoma (NVG) in patients with proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), or branch retinal vein occlusion (BRVO).</p><p><strong>Patients and methods: </strong>A retrospective cohort study using an aggregated, de-identified electronic health record platform (TriNetX), with data from 60+ health care organizations, identified patients with ICD-10 encounter diagnoses for PDR, CRVO, or BRVO and subsequent NVG. NVG cumulative incidence was calculated at 1 day, 1 month, and 3 months post-diagnosis. Risk factors were evaluated after propensity score matching. Incidence (%), relative risk, and 95% CI were reported.</p><p><strong>Results: </strong>Neovascular glaucoma developed in 8.8% of PDR (<i>n</i> = 14,937), 11.6% of CRVO (<i>n</i> = 6,302), and 4.4% of BRVO (<i>n</i> = 2,253) cases. Risk was significantly higher for male patients, age ≥ 70, Black or Hispanic, or with primary open angle glaucoma, hypertension, or diabetes mellitus.</p><p><strong>Conclusion: </strong>Neovascular glaucoma is a common early complication of retinal vascular disease. Several demographic and systemic factors may warrant closer monitoring to prevent vision loss.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-7"},"PeriodicalIF":1.1,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Intravitreal Viscoelastic Injection (PIVOT) for Surgical Optimization in Rhegmatogenous Retinal Detachment With Choroidal Detachment.","authors":"Ritweez Sahu, Devesh Kumawat, Ananya Kaginalkar, Saurabh Verma, Shorya Vardhan Azad, Pradeep Venkatesh","doi":"10.3928/23258160-20260310-02","DOIUrl":"https://doi.org/10.3928/23258160-20260310-02","url":null,"abstract":"<p><strong>Background and objective: </strong>Rhegmatogenous retinal detachment with choroidal detachment (RRDCD) is a challenging situation. This study evaluates the safety and efficacy of preoperative intravitreal viscoelastic injection (PIVOT) in facilitating vitrectomy in RRD-CD.</p><p><strong>Patients and methods: </strong>This consecutive series included eight eyes of eight patients with RRD-CD (CD reaching to equator), managed between December 2024 and April 2025. Healon™ PRO (1% sodium hyaluronate) was injected intravitreally, typically one day prior to vitrectomy, along with topical diflupred-nate, cycloplegics, and oral corticosteroids. Outcome measures were intraocular pressure (IOP), cumulative CD height (by ultrasonography), injection-related adverse events, and intraoperative complications.</p><p><strong>Results: </strong>Mean IOP increased from 4.75 ± 2.05 mmHg at baseline to 10.0 ± 3.34 mmHg on day of surgery (<i>P</i> = .001). Cumulative CD reduced from 15.82 ± 4.88 mm to 5.49 ± 6.01 mm (<i>P</i> = .003). No adverse events were noted. Vitrectomy was safely completed, ensuring adequate silicone oil fill in all eyes.</p><p><strong>Conclusion: </strong>PIVOT combined with anti-inflammatory treatment appears safe and effective in optimizing surgical conditions for RRD-CD.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-6"},"PeriodicalIF":1.1,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RWC Update: Modern One Health Approaches to Novel Challenges in Infectious Uveitis-Emerging Viral Diseases (Part 1); Repair of Closed Funnel Retinal Detachment Through Boston KPro; Choroidal Rupture.","authors":"Ashish Sharma, Lihteh Wu, Steven Bloom, Paulo Stanga, Ashish Sharma, Jessica Carag, Sarah Zohdy, Reem AlAhmadi, Ann-Marie Lobo-Chan, Camila Ventura, Francisco J Rodriguez, Raul Velez-Montoya, Dilraj Grewal, Stacy Andrew, Jonel Steffen, Debbie Espe, Nam Nguyen, Parisa Emami-Naeini, Audina Berrocal, Thomas Albini, Steven Yeh, Baruch D Kuppermann, Jorge Rocha, Kourous Rezaei, Alan J Franklin, Malvika Singh, Manish Nagpal, Kourous A Rezaei","doi":"10.3928/23258160-20260316-01","DOIUrl":"https://doi.org/10.3928/23258160-20260316-01","url":null,"abstract":"","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":"57 4","pages":"207-210"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posttraumatic Stress Disorder and Macular, Choroidal, and Peripapillary Perfusion Using Optical Coherence Tomography and Angiography.","authors":"Grant A Justin, Cason B Robbins, Anita Kundu, Lauren Winslow, Praruj Pant, S Tammy Hsu, Sheriel Choo, Richard Blanch, Sandra S Stinnett, Rupesh Agrawal, Dilraj S Grewal, Sharon Fekrat","doi":"10.3928/23258160-20260127-01","DOIUrl":"10.3928/23258160-20260127-01","url":null,"abstract":"<p><strong>Background and objective: </strong>Posttraumatic stress disorder (PTSD) is a chronic psychiatric condition associated with long-term neurobiological and neurovascular changes. In this study, optical coherence tomography (OCT) and OCT angiography (OCTA) were used to assess macular, choroidal, and peripapillary architecture and microvasculature in patients with PTSD.</p><p><strong>Patients and methods: </strong>Patients with a documented history of PTSD and age- and sex-matched controls were recruited. OCT and OCTA parameters were measured using the Zeiss Cirrus HD-5000 Spectral-Domain OCT with AngioPlex. Primary outcome measure was the associations between differences in OCT and OCTA parameters and PTSD. Secondary outcome measures were the association of OCT and OCTA parameters and other mental illnesses including depression, anxiety, and bipolar disorder, and history of migraine or traumatic brain injury (TBI).</p><p><strong>Results: </strong>Fifty-nine eyes of 32 PTSD patients and 64 eyes of 32 control patients were included. PTSD participants had significantly lower 3 × 3-mm macular perfusion density (PD) and vessel density (VD) (all <i>P</i> ≤ .001), and foveal avascular zone circularity (<i>P</i> < .001) compared to controls. For PTSD subjects with a history of TBI versus those without, there were no significant differences across macular, choroidal, or peripapillary perfusion measurements. However, for PTSD subjects with a history of migraine, there were significantly decreased PD and VD in the 6 × 6-mm circle and inner ring. For associated mental illnesses, there were no differences between PTSD subjects with and without depression, anxiety, or bipolar disorder.</p><p><strong>Conclusion: </strong>Decreased macular perfusion was noted in patients with PTSD. Further investigation is needed to evaluate OCT and OCTA imaging as a noninvasive modality for screening and assessing interventions in patients with PTSD.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"235-241"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy.","authors":"Michael Antonietti, Carolina Mercado, Jorge A Fortun, Thomas A Albini, Sander R Dubovy, William E Smiddy, Stephen G Schwartz, Jaclyn L Kovach","doi":"10.3928/23258160-20260305-01","DOIUrl":"10.3928/23258160-20260305-01","url":null,"abstract":"<p><strong>Background and objective: </strong>This study evaluated the safety of intravitreal avacincaptad pegol in treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</p><p><strong>Patients and methods: </strong>A retrospective review was conducted of patients treated with avacincaptad pegol at Bascom Palmer Eye Institute from January 2024 to January 2025. Adverse events, side effects, and potential risk factors were recorded.</p><p><strong>Results: </strong>The study analyzed 124 eyes from 83 patients (mean age 81.8 ± 6.4 years; 49.4% male; 91.6% White) who received 409 injections in total. Injection intervals varied: 54 eyes monthly, 55 every other month, and others less frequently. The variability in injection frequency was mostly due to patient difficulty with follow-up. Follow-up ranged 3 to 12 months (median: 5 months). Baseline visual acuity averaged 0.40 (approx. 20/50 Snellen) decreasing slightly to 0.38 (20/53 Snellen)-not statistically significant (<i>P</i> = .628). Most eyes (85.2%) were pseudophakic; 47% of patients had prior neovascular AMD treated with anti-vascular endothelial growth factor (anti-VEGF), and 24.2% were simultaneously being treated for active neovascular AMD in the eye receiving avacincaptad pegol. Sixteen eyes had prior pegcetacoplan treatment. Adverse events were rare. One patient developed culture-negative endophthalmitis 4 days after the third injection, presenting with vision loss to hand motion but improving after intravitreal antibiotics. Side effects occurred in 14 eyes (13.8%) across 10 patients, including intraocular pressure elevation (seven eyes), discomfort (four eyes), visual disturbance (two eyes), and subconjunctival hemorrhage (one eye). Five patients discontinued treatment, and one eye (0.8%) had reactivation of neovascular AMD.</p><p><strong>Conclusion: </strong>Our study highlights the safety profile of avacincaptad pegol for GA, with a low incidence of conversion to neovascular AMD, few adverse events, and manageable side effects.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"251-255"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147530691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Inherited Retinal Diseases in the United States: IRIS^® Registry (Intelligent Research in Sight) Analysis.","authors":"Ahmad Al-Moujahed, Md Enamul Haque, Vinit B Mahajan, Rachel Huckfeldt, Suzann Pershing","doi":"10.3928/23258160-20260310-03","DOIUrl":"10.3928/23258160-20260310-03","url":null,"abstract":"<p><strong>Background and objective: </strong>Evaluate disease characteristics and secondary comorbidities following retinitis pigmentosa (RP), choroideremia (CHM), and achromatopsia (ACHM) diagnosis in the United States.</p><p><strong>Patients and methods: </strong>A retrospective cohort study of patients with new RP, CHM, or ACHM diagnoses between January 1, 2013, and December 31, 2019, in the IRIS^® Registry. Main outcome measures were frequency of new RP, CHM, and ACHM, and frequency and hazard ratios for subsequent comorbidities.</p><p><strong>Results: </strong>Overall, 40,302 IRIS Registry patients (58% female) received a new diagnosis of RP, CHM, or ACHM. RP was most common (95%, <i>n</i> = 38,179), followed by ACHM (4%, <i>n</i> = 1583), and CHM (1%, <i>n</i> = 540). RP and CHM presented in younger patients (plurality 45 to 64 years old) compared to ACHM (plurality 75 to 84 years old). In multivariable regression, patients with ACHM were significantly less likely to receive a cataract diagnosis (hazard ratio [HR] = 0.43, 95% CI = 0.39 to 0.47), cataract surgery (HR = 0.64, 95% CI = 0.56 to 0.74), or CME diagnosis (HR = 0.28, 95% CI = 0.23 to 0.33) compared to patients with RP. There was no significant difference between CHM and RP. Rhegmatogenous retinal detachment (RRD) diagnosis and repair were most likely among patients with CHM, compared to patients with RP, and patients with ACHM were less likely to receive an RRD diagnosis but more likely to undergo surgical repair compared to patients with RP (HR = 0.62, 95% CI = 0.49 to 0.79, and HR = 2.57, 95% CI = 1.59 to 4.14, respectively).</p><p><strong>Conclusion: </strong>Patients with inherited retinal diseases can develop treatable ocular conditions that may affect their vision. Cataract and cystoid macular edema (CME) appear to be most associated with RP. Although RRD is rare, it may be disproportionately diagnosed in RP relative to repair rates and was most likely among CHM patients, perhaps reflecting coding practices and/or misdiagnosis.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"257-262"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to the Editor: Intravitreal Methotrexate for Complex Retinal Detachment.","authors":"Ioanna Ploumi, John B Miller","doi":"10.3928/23258160-20260309-01","DOIUrl":"https://doi.org/10.3928/23258160-20260309-01","url":null,"abstract":"","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":"57 4","pages":"269-271"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists: Clinical Considerations and Risk Management for Patients Undergoing Ophthalmic Surgery.","authors":"Caroline R Baumal, Stephanie Choi, Konstantin Balonov, Diana V Do","doi":"10.3928/23258160-20260310-01","DOIUrl":"10.3928/23258160-20260310-01","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity due to their benefits in glycemic control, weight loss, and cardiovascular risk reduction. However, their pharmacologic effect of delayed gastric emptying raises perioperative concerns. Even though ophthalmic procedures are often performed under local or topical anesthesia, there still remains the concern that GLP-1 RA-induced gastroparesis can increase the risk of aspiration. Additionally, adjunctive sedation, conversion to deeper sedation, or general anesthesia is sometimes necessary for ophthalmic surgery. This review outlines the perioperative implications of GLP-1 RA use in ophthalmic surgery, emphasizing the importance of preoperative screening, interdisciplinary coordination, and familiarity with the evolving anesthesia guidelines.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"263-267"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration.","authors":"David C Tabano, Ferhina S Ali, Durga S Borkar, Theodore Leng, Ayesha Ahmed, Stella Ko, Alayna Myrick, Erin Zwick, Amanda Downey, Giulio Barteselli, Rishi P Singh","doi":"10.3928/23258160-20260302-02","DOIUrl":"10.3928/23258160-20260302-02","url":null,"abstract":"<p><strong>Background and objective: </strong>This study evaluated real-world treatment patterns and 1-year outcomes in patients with neovascular age-related macular degeneration (nAMD) initiating faricimab.</p><p><strong>Patients and methods: </strong>FARETINA-AMD was a retrospective study using data from the IRIS^® Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.</p><p><strong>Results: </strong>Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 ± 15.0 (mean ± SD) letters in treatment-naive eyes (<i>P</i> < .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by -53.1 ± 64.8 μm in treatment-naive and -28.5 ± 79.7 μm in previously treated eyes (both <i>P</i> < .0001); 78.4% and 66.8%, respectively, had achieved/maintained C<i>ST</i> ≤ 280 μm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4-3.2 injections) versus the first 6 months (4.0-4.2) of treatment.</p><p><strong>Conclusion: </strong>Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"242-250"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}